Unlocking The Potential Of Nasal Drug Delivery: Strategies For Formulation Success

A strengthened partnership between Quotient Sciences and Ipsen marks an important advancement in the commercial manufacturing of therapies for ultra‑rare diseases. Their renewed collaboration focuses on long‑term production of Sohonos (Palovarotene), a highly potent treatment for Fibrodysplasia Ossificans Progressiva (FOP), a condition affecting fewer than 1,000 patients worldwide. To support this specialized therapy, Ipsen has invested in state‑of‑the‑art containment and material‑handling technologies at the Boothwyn, PA facility, including a Pneumatic Closed Transfer System and a Flexible Dispensing Isolator. These enhancements improve operator safety, minimize cross‑contamination risks, and maintain blend integrity—critical factors in high‑potency manufacturing.

By expanding the facility’s capability to handle compounds with OELs at or below 1 µg/m³, the partnership not only ensures the reliable global supply of FOP therapy but also broadens capacity for additional highly potent products. The investment underscores a shared commitment to supporting underserved patient populations and advancing the manufacturing standards required for niche, small‑volume treatments. Readers will gain insight into how thoughtful infrastructure upgrades and deep technical expertise come together to meet the complex needs of rare disease drug production.